Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis.
about
Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis.Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.Abatacept: A Review in Rheumatoid Arthritis.A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexateExploring immune checkpoints as potential therapeutic targets in atherosclerosis.
P2860
Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Abatacept (CTLA-4Ig) treatment ...... nts with rheumatoid arthritis.
@en
type
label
Abatacept (CTLA-4Ig) treatment ...... nts with rheumatoid arthritis.
@en
prefLabel
Abatacept (CTLA-4Ig) treatment ...... nts with rheumatoid arthritis.
@en
P2093
P2860
P50
P356
P1433
P1476
Abatacept (CTLA-4Ig) treatment ...... nts with rheumatoid arthritis.
@en
P2093
Carl-Walter Steiner
Clemens Scheinecker
Elisabeth Ferner
Günter Steiner
Lisa Göschl
Michael Bonelli
Stephan Blüml
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEV403
P577
2015-12-16T00:00:00Z